Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin.

The purpose of this investigation was to characterize the reaction of alpha 2-antiplasmin (alpha 2AP) and alpha 2-macroglobulin (alpha 2M) with human plasmin bound to rat C6 glioma cells and human umbilical vein endothelial cells (HUVECs). Binding of plasmin (0.1 microM) to C6 cells at 4 degrees C did not cause cell detachment, decrease viability or change cell morphology. The KD and Bmax for the binding of diisopropyl phosphoryl plasmin (DIP-plasmin) to C6 cells were 0.9 microM and 2.6 x 10(6) sites/cell. The dissociation rate constants (koff) for 125I-plasmin were 9.7 x 10(-4) and 4.0 x 10(-4) s-1 at 4 degrees C in the presence and absence of 0.3 microM DIP-plasmin, respectively. Similar constants were determined for 125I-plasminogen and 125I-DIP-plasmin. Neither alpha 2AP nor alpha 2M affected the dissociation of DIP-plasmin. C6 cell-associated 125I-plasmin reacted slowly with alpha 2AP; however, the inhibition rate constants exceeded the koff. alpha 2AP-plasmin complex formed after the plasmin dissociated into solution (reaction pathway 1) and by direct reaction of alpha 2AP with cell-associated enzyme (reaction pathway 2). High concentrations of alpha 2AP favored pathway 2. C6 cell-associated plasmin was also protected from inhibition by alpha 2M. While the same pathways were probably involved in this reaction, alpha 2M was less effective than alpha 2AP as an inhibitor of nondissociated plasmin (pathway 2). When C6 cell-bound plasmin reacted with alpha 2AP, alpha 2AP-plasmin complex was recovered primarily in the medium, suggesting dissociation of complexes formed on the cell surface. Plasmin-receptor dissociation and inhibition experiments were performed at 22 degrees and 37 degrees C, confirming the conclusions of the 4 degrees C studies. Comparable results were also obtained using HUVEC cultures. These studies demonstrate that cell-associated plasmin is protected from inhibition by alpha 2M as well as alpha 2AP. At least two reaction pathways may be demonstrated for the inhibition of plasmin that is initially receptor-bound; however, neither pathway is highly effective, accounting for the "plasmin-protective" activity of the cell surface.

[1]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[2]  J. Plescia,et al.  Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. , 1988, Blood.

[3]  L. Liotta,et al.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.

[4]  G. Peterson,et al.  Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. , 1979, Analytical biochemistry.

[5]  R. Stephens,et al.  Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator , 1981, International journal of cancer.

[6]  E. Plow,et al.  Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells. , 1989, Biochemistry.

[7]  S. Pizzo,et al.  Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. , 1981, The Journal of biological chemistry.

[8]  S. W. Hall,et al.  Expression of plasminogen receptors on C6 glioma cells , 1989, Brain Research.

[9]  D. Strickland,et al.  Characterization of the reaction of plasmin with alpha 2-macroglobulin: effect of antifibrinolytic agents. , 1987, Biochemistry.

[10]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[11]  S. L. Gonias,et al.  Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by α2-antiplasmin, α2-macroglobulin, and antithrombin III in the presence of heparin1 , 1990 .

[12]  P. Burtin,et al.  Limited proteolysis of tumor cells increases their plasmin‐binding ability , 1989, FEBS letters.

[13]  S. W. Hall,et al.  Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro. , 1989, Biochemical and biophysical research communications.

[14]  E. Plow,et al.  Binding and activation of plasminogen on the platelet surface. , 1985, The Journal of biological chemistry.

[15]  E. Plow,et al.  Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis , 1988 .

[16]  R. Silverstein,et al.  Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. , 1985, The Journal of clinical investigation.

[17]  R. Silverstein,et al.  Binding of plasminogen to extracellular matrix. , 1986, The Journal of biological chemistry.

[18]  R. Silverstein,et al.  Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. , 1984, The Journal of clinical investigation.

[19]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[20]  S. W. Hall,et al.  Plasminogen carbohydrate side chains in receptor binding and enzyme activation: A study of C6 glioma cells and primary cultures of rat hepatocytes , 1990, Journal of cellular biochemistry.

[21]  P. McKee,et al.  The binding of human plasminogen to fibrin and fibrinogen. , 1983, The Journal of biological chemistry.

[22]  S. Vandenberg,et al.  Plasminogen binding to rat hepatocytes in primary culture and to thin slices of rat liver , 1989 .

[23]  G. Markus,et al.  The relevance of plasminogen activators to neoplastic growth. A review of recent literature. , 1988, Enzyme.

[24]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[25]  B. Wiman,et al.  On the kinetics of the reaction between human antiplasmin and plasmin. , 1978, European journal of biochemistry.

[26]  N. L. Figler,et al.  Alpha 2-macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Comparison with alpha 2-antiplasmin in simultaneous reaction experiments. , 1988, The Biochemical journal.

[27]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[28]  R. Silverstein,et al.  Binding of Lys-plasminogen to monocytes/macrophages. , 1988, The Journal of clinical investigation.

[29]  B. Wiman,et al.  On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. , 1979, Biochimica et biophysica acta.

[30]  K. Hajjar,et al.  Binding of tissue plasminogen activator to cultured human endothelial cells. , 1987, The Journal of clinical investigation.

[31]  T. Vischer,et al.  Human α2-macroglobulin as an inhibitor of insoluble trypsin , 1989 .

[32]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[33]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[34]  P. Harpel,et al.  Inhibitors of the Fibrinolytic Enzyme System , 1984, Seminars in thrombosis and hemostasis.

[35]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[36]  T. McLellan Electrophoresis buffers for polyacrylamide gels at various pH. , 1982, Analytical biochemistry.

[37]  P. K. Anonick,et al.  Kinetics of the reaction of streptokinase-plasmin complex with purified human and mouse alpha 2-macroglobulin. Implications for mechanism. , 1989, The Biochemical journal.

[38]  J. Bieth,et al.  Kinetics of the inhibition of free and elastin-bound human pancreatic elastase by α1-proteinase inhibitor and α2-macroglobulin , 1989 .

[39]  I. Horváth,et al.  Interaction of plasmin with endothelial cells. , 1984, The Biochemical journal.

[40]  B. Wiman Affinity-chromatographic purification of human α2-antiplasmin , 1980 .

[41]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[42]  E. Plow,et al.  The cell-binding domains of plasminogen and their function in plasma. , 1988, The Journal of biological chemistry.